FDA Not Changing Etep Stance (SRPT) (BMRN) - Leerink

Sarepta Therapeutics (SRPT) Sees Strong Mid-Day Upside

Sarepta Therapeutics (NASDAQ: SRPT) is seeing nice upside movement mid-day after getting slaughtered yesterday on the FDA briefing document. The AdCom is Monday 04/25. Shares last traded up 11% to $12.23.

RBC Sees Odds on Sarepta (SRPT) 9:1 Against

RBC Capital analyst, Simos Simeonidis, threw in the towel on Sarepta Therapeutics (NASDAQ: SRPT) and cut the PT to $7.50. He poses a path for approval but admits that the odds are 9:1 against. The analyst maintained a Sector Perform rating.

The hope for approval for SRPT had relied on its 4-year data and the rebuttal to key conclusions in the January FDA briefing documents. The new documents reiterated FDA's strong views that eteplirsen has not provided sufficient evidence... More

Wedbush Downgrades Sarepta Therapeutic (SRPT) to Neutral (Yesterday)

In a note out yesterday afternoon, Wedbush downgraded Sarepta Therapeutic (NASDAQ: SRPT) from to Neutral with a price target of $14.00 (from $32.00) as the FDA digs in and gets less comfortable with Sarepta's case for eteplirsen.

Analyst Heather Behanna commented, "The amended FDA... More

Buy Sarepta Therapeutic (SRPT) on Sell-Off - Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and $53 price target on Sarepta Therapeutic (NASDAQ: SRPT) after yesterday's sell-off amid new briefing documents ahead of the rescheduled AdComm for eteplirsen. The firm is a buyer on the sell-off.

Messer commented, "The FDA released... More

Sarepta (SRPT) PT Lowered to $23 at Baird as FDA Digs in for a Fight on Eteplirsen

Baird analyst Brian Skorney lowered his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $23.00 (from $47.00) following new FDA briefing documents and increased ambiguity around timeline of confirmatory readout. The firm maintained an Outperform rating.

"Despite Sarepta's, advocates', KOLs', and politicians' attempts to convince FDA that the original assessment was inaccurate, the FDA stands firm in new briefing... More

BioMarin Pharma (BMRN) Announces Enrollment of First BMN 250 Phase 1/2 Patient for MPS IIIB

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2 (IGF2), for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB). Discovered by BioMarin, BMN 250 is being studied in a multicenter, international clinical trial evaluating safety and tolerability, as well as cognitive function of patients with MPS IIIB receiving BMN 250. Designed to restore functional NAGLU activity in the brain, BMN 250 is administered via... More

Oppenheimer Maintains Bullish View on Sarepta (SRPT) Despite Sell-Off on FDA Briefing Documents

Oppenheimer analyst Christopher Marai is maintaining his Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) despite the massive sell-off on the FDA released updated briefing documents for SRPT's Monday Adcom.

Marai commented, "FDA was mostly unchanged in its analysis,... More

CRL 'Most Logical Outcome' for Sarepta's (SRPT) Eteplirsen - Janney Montgomery Scott

Janney Montgomery Scott Weighed in on Sarepta Therapeutics (NASDAQ: SRPT) following today's FDA briefing... More

Sarepta Therapeutics (SRPT) Sees Quick Sell-Off Following FDA Briefing Docs

Sarepta Therapeutics (NASDAQ: SRPT) trades down a quick 15% following posting of the FDA briefing documents.

Sarepta Therapeutics (SRPT) on watch as FDA briefing documents hit

Sarepta Therapeutics (NASDAQ: SRPT) on watch as FDA briefing documents hit.